Caribou Biosciences (NASDAQ:CRBU) & Titan Pharmaceuticals (NASDAQ:TTNP) Head-To-Head Review

Caribou Biosciences (NASDAQ:CRBU) and Titan Pharmaceuticals (NASDAQ:TTNP) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, earnings and dividends.

Institutional and Insider Ownership

77.5% of Caribou Biosciences shares are held by institutional investors. Comparatively, 31.5% of Titan Pharmaceuticals shares are held by institutional investors. 9.5% of Caribou Biosciences shares are held by company insiders. Comparatively, 24.9% of Titan Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Caribou Biosciences and Titan Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Caribou Biosciences	-372.78%	-34.76%	-29.58%
Titan Pharmaceuticals	N/A	-87.90%	-75.11%

Earnings and Valuation

This table compares Caribou Biosciences and Titan Pharmaceuticals”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Caribou Biosciences	$33.11 million	5.35	-$102.07 million	($1.39)	-1.41
Titan Pharmaceuticals	$180,000.00	20.26	-$5.57 million	N/A	N/A

Titan Pharmaceuticals has lower revenue, but higher earnings than Caribou Biosciences.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Caribou Biosciences and Titan Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Caribou Biosciences	0	1	3	0	2.75
Titan Pharmaceuticals	0	0	0	0	N/A

Caribou Biosciences currently has a consensus price target of $11.25, indicating a potential upside of 473.98%. Given Caribou Biosciences’ higher probable upside, research analysts clearly believe Caribou Biosciences is more favorable than Titan Pharmaceuticals.

Risk & Volatility

Caribou Biosciences has a beta of 2.27, suggesting that its stock price is 127% more volatile than the S&P 500. Comparatively, Titan Pharmaceuticals has a beta of 1.08, suggesting that its stock price is 8% more volatile than the S&P 500.

Summary

Caribou Biosciences beats Titan Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

About Caribou Biosciences

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

About Titan Pharmaceuticals

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder. The company was founded in 1991 and is based in South San Francisco, California.